Sialic Acid-Modified Nanoparticles-New Approaches in the Glioma Management-Perspective Review

Int J Mol Sci. 2021 Jul 13;22(14):7494. doi: 10.3390/ijms22147494.

Abstract

The cell surface is covered by a dense and complex network of glycans attached to the membrane proteins and lipids. In gliomas, the aberrant sialylation, as the final stage of glycosylation, is an important regulatory mechanism of malignant cell behavior and correlates with worse prognosis. Better understanding of the role of sialylation in cellular and molecular processes opens a new way in the development of therapeutic tools for human brain tumors. According to the recent clinical observation, the cellular heterogeneity, activity of brain cancer stem cells (BCSCs), immune evasion, and function of the blood-brain barrier (BBB) are attractive targets for new therapeutic strategies. In this review, we summarize the importance of sialic acid-modified nanoparticles in brain tumor progression.

Keywords: Siglecs; blood–brain barrier; glioma; nanoparticles; sialic acid.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Blood-Brain Barrier / drug effects*
  • Brain Neoplasms / drug therapy*
  • Glioma / drug therapy*
  • Glioma / pathology
  • Glycosylation
  • Humans
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Polysaccharides / chemistry*

Substances

  • Antineoplastic Agents
  • Polysaccharides